EMBO Molecular Medicine (Sep 2019)

CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia

  • Talveen S Purba,
  • Kayumba Ng'andu,
  • Lars Brunken,
  • Eleanor Smart,
  • Ellen Mitchell,
  • Nashat Hassan,
  • Aaron O'Brien,
  • Charlotte Mellor,
  • Jennifer Jackson,
  • Asim Shahmalak,
  • Ralf Paus

DOI
https://doi.org/10.15252/emmm.201911031
Journal volume & issue
Vol. 11, no. 10
pp. 1 – 16

Abstract

Read online

Abstract Taxanes are a leading cause of severe and often permanent chemotherapy‐induced alopecia. As the underlying pathobiology of taxane chemotherapy‐induced alopecia remains poorly understood, we investigated how paclitaxel and docetaxel damage human scalp hair follicles in a clinically relevant ex vivo organ culture model. Paclitaxel and docetaxel induced massive mitotic defects and apoptosis in transit amplifying hair matrix keratinocytes and within epithelial stem/progenitor cell‐rich outer root sheath compartments, including within Keratin 15+ cell populations, thus implicating direct damage to stem/progenitor cells as an explanation for the severity and permanence of taxane chemotherapy‐induced alopecia. Moreover, by administering the CDK4/6 inhibitor palbociclib, we show that transit amplifying and stem/progenitor cells can be protected from paclitaxel cytotoxicity through G1 arrest, without premature catagen induction and additional hair follicle damage. Thus, the current study elucidates the pathobiology of taxane chemotherapy‐induced alopecia, highlights the paramount importance of epithelial stem/progenitor cell‐protective therapy in taxane‐based oncotherapy, and provides preclinical proof‐of‐principle in a healthy human (mini‐) organ that G1 arrest therapy can limit taxane‐induced tissue damage.

Keywords